2LARTH®, a micro-immunotherapy medicine, exerts anti-inflammatory effects in vitro and reduces TNF-α and IL-1β secretion
Ilaria Floris,1 Kurt Appel,2 Thorsten Rose,2 Beatrice Lejeune3 1Clinical Affairs, Labo’Life France, Moutiers-Sous-Chantemerle, France; 2VivaCell Biotechnology GmbH, Denzlingen, Germany; 3Clinical Affairs, Labo’Life Belgium, Gembloux, Belgium Background: Tumor necrosis factor-&...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2018
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/5028a473e57f43d7bfd20b8c65bd0606 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:5028a473e57f43d7bfd20b8c65bd0606 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:5028a473e57f43d7bfd20b8c65bd06062021-12-02T03:31:29Z2LARTH®, a micro-immunotherapy medicine, exerts anti-inflammatory effects in vitro and reduces TNF-α and IL-1β secretion1178-7031https://doaj.org/article/5028a473e57f43d7bfd20b8c65bd06062018-10-01T00:00:00Zhttps://www.dovepress.com/2larthreg-a-micro-immunotherapy-medicine-exerts-anti-inflammatory-effe-peer-reviewed-article-JIRhttps://doaj.org/toc/1178-7031Ilaria Floris,1 Kurt Appel,2 Thorsten Rose,2 Beatrice Lejeune3 1Clinical Affairs, Labo’Life France, Moutiers-Sous-Chantemerle, France; 2VivaCell Biotechnology GmbH, Denzlingen, Germany; 3Clinical Affairs, Labo’Life Belgium, Gembloux, Belgium Background: Tumor necrosis factor-α (TNF-α) and IL-1β are 2 pro-inflammatory cytokines known to be involved in rheumatic diseases. The therapeutic strategy used in micro-immunotherapy (MI) to reduce chronic inflammation and attenuate pain consists in mainly targeting these 2 cytokines. 2LARTH® is a sublingually administered medicine consisting of lactose-saccharose globules impregnated with ethanolic preparations of immune mediators and nucleic acids at ultra-low doses. Purpose: The aim of the study is to explore the effect of the MI medicine on TNF-α and IL-1β secretion in human primary enriched monocytes exposed to lipopolysaccharide (LPS). Materials and methods: Placebo and active globules were diluted in culture medium to test 5 lactose-saccharose globules concentrations (from 1.75 to 22 mM). Freshly isolated enriched monocytes from 6 healthy donors were treated with or without LPS (10 ng/mL), LPS+ placebo, or LPS+ 2LARTH® for 24 hours. IL-1β, TNF-α, and IL-6 release were evaluated by ELISA. Results: The medicine has significantly decreased the level of IL-1β secretion compared with placebo at these concentrations: 22 mM (P<0.0001), 11 mM (P=0.0086), 5.5 mM (P= 0.0254), and compared with untreated LPS control at these concentrations: 22 mM, 11 mM (P=0.0008), and 5.5 mM (P=0.002). The effect of active globules on the reduction of TNF-α release is significant compared with placebo at these concentrations: 22 mM (P=0.0018), 11 mM (P=0.0005), 5.5 mM (P=0.0136), and compared with untreated LPS control at these concentrations: 22 mM (P=0.0021), 11 mM (P=0.0017), 5.5 mM (P=0.0052) and 2.25 mM (P=0.0196). Besides, IL-6 secretion decreased compared with placebo at 22 mM (P=0.0177) and 11 mM (P=0.0031). Conclusion: The results indicate that the tested product exerts significant anti-inflammatory effects on human LPS-stimulated monocytes. Keywords: ultra-low doses, hormesis, chronic inflammation, rheumatic diseasesFloris IAppel KRose TLejeune BDove Medical PressarticleUltra-low doseshormesischronic inflammationrheumatic diseasesPathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 11, Pp 397-405 (2018) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Ultra-low doses hormesis chronic inflammation rheumatic diseases Pathology RB1-214 Therapeutics. Pharmacology RM1-950 |
| spellingShingle |
Ultra-low doses hormesis chronic inflammation rheumatic diseases Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Floris I Appel K Rose T Lejeune B 2LARTH®, a micro-immunotherapy medicine, exerts anti-inflammatory effects in vitro and reduces TNF-α and IL-1β secretion |
| description |
Ilaria Floris,1 Kurt Appel,2 Thorsten Rose,2 Beatrice Lejeune3 1Clinical Affairs, Labo’Life France, Moutiers-Sous-Chantemerle, France; 2VivaCell Biotechnology GmbH, Denzlingen, Germany; 3Clinical Affairs, Labo’Life Belgium, Gembloux, Belgium Background: Tumor necrosis factor-α (TNF-α) and IL-1β are 2 pro-inflammatory cytokines known to be involved in rheumatic diseases. The therapeutic strategy used in micro-immunotherapy (MI) to reduce chronic inflammation and attenuate pain consists in mainly targeting these 2 cytokines. 2LARTH® is a sublingually administered medicine consisting of lactose-saccharose globules impregnated with ethanolic preparations of immune mediators and nucleic acids at ultra-low doses. Purpose: The aim of the study is to explore the effect of the MI medicine on TNF-α and IL-1β secretion in human primary enriched monocytes exposed to lipopolysaccharide (LPS). Materials and methods: Placebo and active globules were diluted in culture medium to test 5 lactose-saccharose globules concentrations (from 1.75 to 22 mM). Freshly isolated enriched monocytes from 6 healthy donors were treated with or without LPS (10 ng/mL), LPS+ placebo, or LPS+ 2LARTH® for 24 hours. IL-1β, TNF-α, and IL-6 release were evaluated by ELISA. Results: The medicine has significantly decreased the level of IL-1β secretion compared with placebo at these concentrations: 22 mM (P<0.0001), 11 mM (P=0.0086), 5.5 mM (P= 0.0254), and compared with untreated LPS control at these concentrations: 22 mM, 11 mM (P=0.0008), and 5.5 mM (P=0.002). The effect of active globules on the reduction of TNF-α release is significant compared with placebo at these concentrations: 22 mM (P=0.0018), 11 mM (P=0.0005), 5.5 mM (P=0.0136), and compared with untreated LPS control at these concentrations: 22 mM (P=0.0021), 11 mM (P=0.0017), 5.5 mM (P=0.0052) and 2.25 mM (P=0.0196). Besides, IL-6 secretion decreased compared with placebo at 22 mM (P=0.0177) and 11 mM (P=0.0031). Conclusion: The results indicate that the tested product exerts significant anti-inflammatory effects on human LPS-stimulated monocytes. Keywords: ultra-low doses, hormesis, chronic inflammation, rheumatic diseases |
| format |
article |
| author |
Floris I Appel K Rose T Lejeune B |
| author_facet |
Floris I Appel K Rose T Lejeune B |
| author_sort |
Floris I |
| title |
2LARTH®, a micro-immunotherapy medicine, exerts anti-inflammatory effects in vitro and reduces TNF-α and IL-1β secretion |
| title_short |
2LARTH®, a micro-immunotherapy medicine, exerts anti-inflammatory effects in vitro and reduces TNF-α and IL-1β secretion |
| title_full |
2LARTH®, a micro-immunotherapy medicine, exerts anti-inflammatory effects in vitro and reduces TNF-α and IL-1β secretion |
| title_fullStr |
2LARTH®, a micro-immunotherapy medicine, exerts anti-inflammatory effects in vitro and reduces TNF-α and IL-1β secretion |
| title_full_unstemmed |
2LARTH®, a micro-immunotherapy medicine, exerts anti-inflammatory effects in vitro and reduces TNF-α and IL-1β secretion |
| title_sort |
2larth®, a micro-immunotherapy medicine, exerts anti-inflammatory effects in vitro and reduces tnf-α and il-1β secretion |
| publisher |
Dove Medical Press |
| publishDate |
2018 |
| url |
https://doaj.org/article/5028a473e57f43d7bfd20b8c65bd0606 |
| work_keys_str_mv |
AT florisi 2larthregamicroimmunotherapymedicineexertsantiinflammatoryeffectsinvitroandreducestnfalphaandil1betasecretion AT appelk 2larthregamicroimmunotherapymedicineexertsantiinflammatoryeffectsinvitroandreducestnfalphaandil1betasecretion AT roset 2larthregamicroimmunotherapymedicineexertsantiinflammatoryeffectsinvitroandreducestnfalphaandil1betasecretion AT lejeuneb 2larthregamicroimmunotherapymedicineexertsantiinflammatoryeffectsinvitroandreducestnfalphaandil1betasecretion |
| _version_ |
1718401728254050304 |